The corona crisis has reduced the demand for hearing aids, which has led WS Audiology to send 700 of its 900 Danish employees home on leave paid for by the Danish state. "It is too expensive for us to keep all of our employees working with the current demand," the company says.
Although research director Johan Luthman is disappointed that Parkinson's drug foliglurax has performed so badly in clinical trials that the project is being shut down, he still sees lots of potential in the newly-purchased Abide portfolio - though this has also included one fiasco.
Zealand Pharma has sent dasiglucagon, which is a treatment for low blood sugar administered through auto-injector Hypopal, for approval at the FDA.
Novo Nordisk-owned antibiotics producer Xellia Pharmaceuticals has publicized a strong year-end report with a record-high profit. However, the company still expects a difficult 2020.
Estron, which supplies equipment to the world's largest hearing aid manufacturers, is steaming ahead one year after a change in ownership. Despite massive investments in the future, the top and bottom lines are growing significantly - but the lurking coronavirus danger may have serious consequences for 2020.
At the Leo Foundation, rewards from the share boom in 2019 have been reaped. Although the markets are currently in turmoil, this hasn't made the foundation nervous - it sees opportunities in the situation.
Genmab expects to survive the corona crisis relatively unscathed, and still wants to find a partner for its drug epcoritamab, one of the company's biggest hopes.
Existing and new shareholders did not buy quite as many shares in its recent share issue as Bavarian Nordic had hoped for, but CEO Paul Chaplin is still satisfied with the result considering the current market turmoil.
The now outgoing board chairman of pharmaceutical company Azanta calls the fact that the 16-year-old Danish company has been sold to Dutch group a "fairytale". Norgine is the right company to increase sales of Azanta's main product, he says.
Biotech company Inprother has found a replacement for Mathias Kroll, who was only CEO at the company for six months. The new CEO comes from the same role at Cytovac, and his first job will be to complete a DKK 150 million financing round. This may be harder than expected.
Boehringer Ingelheim called off a collaboration to develop amylin analog drugs for obesity and diabetes with Zealand Pharma on Friday. Zealand must now decide whether to develop an amylin analog itself, or scrap the project.
300-400 coronavirus patients will participate in a Danish trial using malaria medicine as a possible treatment for the virus, which is spreading worldwide. Researchers will know whether it was successful in 4-7 months.
The European industry association for medtech companies has urged the EU commission to press pause on the new, tighter regulations for approval of medical devices in Europe. The corona crisis makes it impossible to live up to the new rules before they come into force, the association warns.
Through the purchase of British company Pilatus in 2019, Orifarm has established a third business arm - but this will not be reflected in the accounts for some time.
Increased competition and a price squeeze within the cochlear implant industry has led Australian firm Cochlear to terminate its contract with its Danish provider Danaflex, which it has worked with for 30 years.
Kasim Kutay, CEO of Novo Holdings, is not afraid to invest in new companies even though the stock markets are bottoming out. On the contrary, the Novo-owner has its sights set on several companies that were otherwise too expensive.
On Monday, a regulatory change came into force, meaning that it will now be possible to get biosimilar insulin approved in the USA. The former head of the FDA called it a paradigm shift, but analysts doubt it will topple the insulin market.
While Novo Nordisk's hemophilia hopeful concizumab has encountered serious problems in phase III, the company is focusing on the development of another treatment, hoping to outdo Roche's market-leading drug Hemlibra.
Biotech company Oncology Venture has received positive feedback from the FDA after an introductory meeting about the path to approval for the company's cancer drug. The market potential is DKK 43 billion, but there is a way to go before the Danish company can make its US debut.
Mads Krogsgaard Thomsen, chief science officer at Novo Nordisk, is not hopeful about the future of hemophilia drug concizumab after three patients developed blood clots during clinical trials. Now the company will examine the cause and subsequently determine concizumab's fate.
The first time pharmaceutical companies test a new drug on humans, it is a requirement that an intensive care team is at the ready at the hospital where the study is being conducted. As more corona patients are admitted, capacity is being squeezed, and it is only a matter of time before Rigshospitalet's special Phase I Unit has to stop recruiting new patients.
It has "extraordinary consequences" for the conduct of clinical trials in Denmark that the country is hit by the global coronavirus pandemic, the Danish Medicines Agency writes. Pharmaceutical companies are monitoring the situation.
The dream of an initial public offering in Denmark is still alive at picture diagnostics firm Visiopharm, which was a hair's breadth away from entering the stock exchange in Stockholm in 2018. But new investors gave the company 100 million good reasons to choose Copenhagen - and their preferences haven't changed.
This month, Zealand Pharma is sending its first approval application to the FDA, and not even coronavirus can stop them. The company has an eventful year ahead, which is shown in the financial expectations for 2020.
A German vaccine company which is developing a coronavirus vaccine speaks to the EU commission chair, Ursula von der Leyen, via video chat on Monday afternoon.
